文献速递肺血管病与心包/心肌炎

SOX17增强子变异通过破坏转录因子结合降低表达促发肺动脉高压

SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.
PubMed 文献 · Circulation · 2023-04-17

该研究探讨SOX17增强子区PAH风险变异的功能机制。CRISPR和EMSA证实风险等位基因改变HOXA5和ROR-α结合,降低SOX17表达,导致hPAEC功能障碍;小鼠增强子敲除加重缺氧或SU5416/缺氧诱导的肺动脉高压,连接图谱分析可识别逆转转录组特征的化合物。

要点

  • SOX17增强子风险变异通过差异结合HOXA5/ROR-α降低SOX17表达。
  • SOX17缺失损害hPAEC屏障功能并促进凋亡与增殖。
  • 增强子敲除小鼠加重缺氧及SU5416/缺氧诱导的肺动脉高压。

核心结论

  • SOX17启动子上游常见PAH风险变异至少部分通过HOXA5和ROR-α差异结合降低内皮SOX17表达,进而导致hPAEC功能障碍和PAH。

研究设计与样本

  • 采用CRISPR抑制/缺失和siRNA调控SOX17表达,EMSA验证变异差异结合,hPAEC功能实验评估SOX17缺失后果,连接图谱预测 rescue 化合物,SOX17-signal 1增强子区缺失小鼠(SOX17-4593/enhKO)在慢性缺氧和SU5416/缺氧下进行表型分析。

主要发现

  • CRISPR抑制SOX17-signal 2和缺失SOX17-signal 1特异性降低SOX17表达。
  • EMSA显示hPAEC核蛋白对两个SOX17信号的风险与非风险等位基因存在差异结合。
  • hPAEC转录组分析揭示SOX17沉默改变PAH相关通路包括细胞外基质调控。
  • SOX17沉默导致hPAEC凋亡和增殖增加及屏障功能紊乱。
  • 小鼠SOX17增强子敲除降低肺SOX17表达,导致更严重的肺血管渗漏及缺氧或SU5416/缺氧诱导的肺动脉高压。

临床怎么用

  • 增强子区风险变异可作为PAH遗传风险解释的候选机制。
  • HOXA5和ROR-α可能是SOX17调控的关键转录因子。
  • 连接图谱识别的化合物可能为逆转SOX17功能障碍提供候选药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary arterial hypertension (PAH) is a rare disease characterized by remodeling of the pulmonary arteries, increased vascular resistance, and right-sided heart failure. Genome-wide association studies of idiopathic/heritable PAH established novel genetic risk variants, including conserved enhancers upstream of transcription factor (TF) SOX17 containing 2 independent signals. SOX17 is an important TF in embryonic development and in the homeostasis of pulmonary artery endothelial cells (hPAEC) in the adult. Rare pathogenic mutations in SOX17 cause heritable PAH. We hypothesized that PAH risk alleles in an enhancer region impair TF-binding upstream of SOX17, which in turn reduces SOX17 expression and contributes to disturbed endothelial cell function and PAH development. METHODS: CRISPR manipulation and siRNA were used to modulate SOX17 expression. Electromobility shift assays were used to confirm in silico-predicted TF differential binding to the SOX17 variants. Functional assays in hPAECs were used to establish the biological consequences of SOX17 loss. In silico analysis with the connectivity map was used to predict compounds that rescue disturbed SOX17 signaling. Mice with deletion of the SOX17-signal 1 enhancer region (SOX17-4593/enhKO) were phenotyped in response to chronic hypoxia and SU5416/hypoxia. RESULTS: CRISPR inhibition of SOX17-signal 2 and deletion of SOX17-signal 1 specifically decreased SOX17 expression. Electromobility shift assays demonstrated differential binding of hPAEC nuclear proteins to the risk and nonrisk alleles from both SOX17 signals. Candidate TFs HOXA5 and ROR-α were identified through in silico analysis and antibody electromobility shift assays. Analysis of the hPAEC transcriptomes revealed alteration of PAH-relevant pathways on SOX17 silencing, including extracellular matrix regulation. SOX17 silencing in hPAECs resulted in increased apoptosis, proliferation, and disturbance of barrier function. With the use of the connectivity map, compounds were identified that reversed the SOX17-dysfunction transcriptomic signatures in hPAECs. SOX17 enhancer knockout in mice reduced lung SOX17 expression, resulting in more severe pulmonary vascular leak and hypoxia or SU5416/hypoxia-induced pulmonary hypertension. CONCLUSIONS: Common PAH risk variants upstream of the SOX17 promoter reduce endothelial SOX17 expression, at least in part, through differential binding of HOXA5 and ROR-α. Reduced SOX17 expression results in disturbed hPAEC function and PAH. Existing drug compounds can reverse the disturbed SOX17 pulmonary endothelial transcriptomic signature.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Walters R, Vasilaki E, Aman J, et al. SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension. Circulation. 2023. PMID: 37066790. doi:10.1161/CIRCULATIONAHA.122.061940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。